QUESTCOR PHARMACEUTICALS INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2014-08-20: Form 8-K; Period of report 2014-08-15; Description 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Details 5.03.
- 2014-08-14: Form 8-K; Period of report 2014-08-14; Description 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events; Details 2.01.
- 2014-07-30: Form 8-K; Period of report 2014-07-29; Description 8.01 Other Events; Details 8.01.
- 2014-07-25: Form 8-K; Period of report 2014-07-24; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2014-08-20 | 8-K | 2014-08-15 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On August 14, 2014, pursuant to the Agreement and Plan of Merger (the “Merger Agreement”), dated as of April 5, 2014, among Questcor Pharmaceuticals, Inc. (the “Company”), Mallinckrodt plc (“Mallinckrodt”) and Quincy Merger Sub, Inc. (“Merger Sub”), Merger Sub merged with and into the Company, with the Company being the surviving entity (the “Merger”). | d778808d8k.htm |
| 2014-08-14 | 8-K | 2014-08-14 | 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events | 2.01 On August 14, 2014, pursuant to the Agreement and Plan of Merger (the “Merger Agreement”), dated as of April 5, 2014, among Questcor Pharmaceuticals, Inc. (the “Company”), Mallinckrodt plc (“Mallinckrodt”) and Quincy Merger Sub, Inc. (“Merger Sub”), Merger Sub merged with and into the Company, with the Company being the surviving entity (the “Merger”). 3.01 On August 14, 2014, in connection with the Merger, the Company notified the NASDAQ Stock Market (“NASDAQ”) that the Merger had been completed and requested that trading of Company common stock on NASDAQ be suspended after the close of trading on August 14, 2014. 3.03 In connection with the Merger, on August 14, 2014 each share of Company common stock was cancelled and automatically converted into the right to receive the Merger Consideration. 5.01 As a result of the Merger, a change of control of the Company occurred and the Company became a wholly owned subsidiary of Mallinckrodt. 5.02 At the Effective Time, each member of the Company’s board of directors ceased to be a director of the Company. 5.07 On August 14, 2014, the Company held a special meeting of shareholders (the “Special Meeting”) to consider certain proposals related to the Merger Agreement, which provides, among other things and subject to the terms and conditions set forth therein, that the Company will be merged with and into Merger Sub with the Company as the surviving entity. 8.01 On August 14, 2014, the Company and Mallinckrodt issued a joint press release announcing (1) the results of the Special Meeting and (2) the results of the extraordinary general meeting of shareholders of Mallinckrodt held on August 14, 2014. | d772821d8k.htm |
| 2014-07-30 | 8-K | 2014-07-29 | 8.01 Other Events | 8.01 As previously disclosed at page 170 of the definitive joint proxy statement/prospectus dated July 11, 2014 (the “Definitive Joint Proxy Statement/Prospectus”) under the heading “Litigation Relating to the Transaction,” certain actions were filed by putative shareholders of Questcor Pharmaceuticals, Inc. (“Questcor”) and were subsequently consolidated in the California Superior Court. | d765179d8k.htm |
| 2014-07-25 | 8-K | 2014-07-24 | 2.02 Results of Operations and Financial Condition | 2.02 On July 24, 2014, Questcor Pharmaceuticals, Inc. (the “Company”) announced via press release certain operating and financial results for the quarter ended June 30, 2014. | d762553d8k.htm |
| 2014-07-10 | 8-K | 2014-07-10 | 8.01 Other Events | 8.01 Questcor Pharmaceuticals, Inc. (the “Company”) is filing this Current Report on Form 8-K in connection with the preparation of the Registration Statement on Form S-4 of Mallinckrodt plc (“Mallinckrodt”) (File No. 333-196054) (the “Registration Statement”), which includes the Company’s Proxy Statement relating to its pending merger transaction with Mallinckrodt. | d755101d8k.htm |
| 2014-05-16 | 8-K | 2014-05-13 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 13, 2014, Questcor Pharmaceuticals, Inc. (the “Company”) entered into an amendment (the “Asarpota Amendment”) to the severance agreement with Rajesh Asarpota, the Company’s Senior Vice President, Chief Financial Officer. | d728237d8k.htm |
| 2014-05-06 | 8-K | 2014-04-28 | 2.02 Results of Operations and Financial Condition | 2.02 On April 28, 2014, Questcor Pharmaceuticals, Inc. (the “Company”) announced via press release certain operating and financial results for the quarter ended March 31, 2014. | d723174d8k.htm |
| 2014-04-07 | 8-K | 2014-04-05 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 1.01 On April 5, 2014, Questcor Pharmaceuticals, Inc., a California corporation (the “Company”), Mallinckrodt plc, an Irish public limited company (“Parent”), and Quincy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), entered into an Agreement and Plan of Merger, dated as of April 5, 2014 (the “Merger Agreement”), pursuant to which, subject to the terms and conditions set forth in the Merger Agreement, Merger Sub will be merged with and into the Company (the “Merger”), with the Company continuing as the surviving corporation (the “Surviving Corporation”). 5.02 On April 5, 2014, the Board of Directors of the Company approved an amendment (the “Plan Amendment”) to the Company’s Amended and Restated 2006 Equity Incentive Plan (the “Plan”). 7.01 On April 7, 2014, the Company and Parent issued a joint press release announcing the execution of the Merger Agreement described above. | d708240d8k.htm |
| 2014-03-03 | 8-K | 2014-02-25 | 2.02 Results of Operations and Financial Condition | 2.02 On February 25, 2014, Questcor Pharmaceuticals, Inc. (the “Company”) announced via press release certain operating and financial results for the quarter and year ended December 31, 2013. | d687381d8k.htm |
| 2014-03-03 | 8-K | 2014-03-03 | 7.01 Regulation FD Disclosure | 7.01 Questcor has a strong track record of providing therapies to patients with unmet medical needs. | d685647d8k.htm |
| 2014-02-12 | 8-K | 2014-02-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) Resignation of Named Executive Officer. | d677744d8k.htm |
| 2014-01-23 | 8-K | 2014-01-23 | 8.01 Other Events | 8.01 During January 13-16, 2014, Questcor Pharmaceuticals participated in the J. P. Morgan Global Healthcare Conference in San Francisco. | d664241d8k.htm |
| 2014-01-13 | 8-K | 2014-01-13 | 7.01 Regulation FD Disclosure | 7.01 Commencing on January 13, 2014, Questcor Pharmaceuticals, Inc. will utilize an updated presentation for investor relations purposes. | d658915d8k.htm |
| 2014-01-13 | 8-K | 2014-01-13 | 7.01 Regulation FD Disclosure | 7.01 Patient support programs, including co-pay assistance programs and patient assistance programs, are common for specialty pharmaceutical products. | d655211d8k.htm |